REG - hVIVO PLC - Grant of awards under Long Term Incentive Plan

hVIVOAnnouncement

29/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260529:nRSc1378Ga&default-theme=true

RNS Number : 1378G  hVIVO PLC  29 May 2026

 

hVIVO plc

("hVIVO, the "Company" or the "Group")

 

Grant of awards under Long Term Incentive Plan

 

London, UK - 29 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service
international clinical development partner and the world leader in human
challenge trials, announces that on 28 May 2026, the Company awarded
10,159,068 options under the hVIVO Long Term Incentive Plan 2024 to certain
senior management, including its Chief Executive Officer and Chief Financial
Officer as set out in the table below. The award is over ordinary shares of
£0.001 ("Ordinary Shares") in the form of options to acquire Ordinary Shares
at nominal value ("LTIP Awards").

 

 Executive          Role                     Number of LTIP Awards
 Yamin 'Mo' Khan    Chief Executive Officer  6,126,238
 Stephen Pinkerton  Chief Financial Officer  2,289,604

 

The LTIP Awards will vest on the third anniversary of grant subject to meeting
a minimum absolute total shareholder return (TSR) of 10% CAGR and mid-single
digit £ million adjusted EBITDA,  weighted equally, over the three-year
period ending 31 December 2028.

25% of the LTIP Awards will vest on meeting the minimum threshold performance
criteria outlined above, with vesting thereafter on a straight-line basis up
to meeting a maximum performance target which would be achieved in the event
of a 20% absolute TSR being met and a significant increase in adjusted EBITDA
from the minimum threshold number.

The awards are subject to malus and clawback provisions. In making its
determination in relation to the achievement of any performance target or
condition under these Rules, the Remuneration Committee may, in line with the
UK Corporate Governance Code, exercise its discretion to override formulaic
outcomes. This includes, without limitation, to reflect overall corporate
performance, the value created for shareholders, or where the business has
suffered an exceptional negative event.

For further information please contact:

 

 hVIVO plc                                                                           +44 (0) 20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                                                      +44 (0) 20 7220 0500
 Geoff Nash, Callum Davidson

 Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                                                            +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Euronext Growth Adviser and Joint Broker)                                                         +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 ICR Healthcare (Financial PR & IR)                                                  hVIVO@icrhealthcare.com

 Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (AIM: HVO) is a purpose-built, full-service
international clinical development partner and the global leader in human
challenge trials, serving seven of the world's ten largest biopharma
companies.

 

The Company has an end-to-end platform designed to bring important medicines
to patients faster: spanning preclinical strategy, first‑in‑human studies,
Phase II patient trials and specialist laboratory services, delivered through
a large participant database, wholly owned sites and laboratories across the
UK and Germany.

 

With a combined Group heritage of more than 100 years, hVIVO delivers an
accelerated pathway to clinical proof-of-concept through four integrated
service lines: Consulting, Clinical Trials, Human Challenge Trials, and
Laboratories.

 

·    Consulting
(https://www.hvivo.com/solutions/drug-development-consulting) provides
expert-led preclinical and clinical strategy, encompassing non-clinical,
clinical, CMC, pharmacokinetics, data management, biostatistics, and
regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials (https://www.hvivo.com/solutions/clinical/) offers
Phase I/II CRO services, Phase II/III site services across the UK and Germany,
and specialist recruitment through FluCamp (http://www.flucamp.com/) ,
Europe's largest recruitment database.

·    Human Challenge Trials
(https://www.hvivo.com/solutions/human-challenge) leverages hVIVO's
state-of-the-art quarantine facility in London - the largest of its kind
worldwide - to deliver fast, controlled, high-quality efficacy data through
guaranteed viral exposure.

·    Laboratories (https://www.hvivo.com/solutions/laboratory) provides
cutting-edge virology and immunology laboratory services, including biobanking
and sample storage, supporting both challenge trials and standalone client
studies.

 

The information set out below is provided in accordance with the requirements
of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

 1    Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                                         Yamin 'Mo' Khan
 2    Reason for the notification
 (a)  Position/status                                              Chief Executive Officer

 (b)  Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 (a)  Name                                                         hVIVO plc
 (b)  LEI                                                          213800VT5KBM7JLIV118
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the financial instrument, type of instrument  Options over Ordinary shares of £0.001 pence each

      Identification code                                          ISIN GB00B9275X97

 (b)  Nature of the transaction                                    Award of options pursuant to hVivo plc 2024 Long Term Incentive Plan
 (c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                        £0.001    6,126,238

 (d)  Aggregated information                                       N/A

      -         Aggregated volume

      -         Price
 (e)  Date of the transaction                                      28 May 2026
 (f)  Place of the transaction                                     Outside a trading venue

(d)

Aggregated information

-         Aggregated volume

-         Price

N/A

(e)

Date of the transaction

28 May 2026

(f)

Place of the transaction

Outside a trading venue

 

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                                         Stephen Pinkerton
 2    Reason for the notification
 (a)  Position/status                                              Chief Financial Officer

 (b)  Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 (a)  Name                                                         hVIVO plc

 (b)  LEI                                                          213800VT5KBM7JLIV118

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the financial instrument, type of instrument  Options over Ordinary shares of £0.001 pence each

      Identification code                                          ISIN GB00B9275X97

 (b)  Nature of the transaction                                    Award of options pursuant to hVIVO plc 2024 Long Term Incentive Plan
 (c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                        £0.001    2,289,604

 (d)  Aggregated information                                       N/A

      -         Aggregated volume

      -         Price
 (e)  Date of the transaction                                      28 May 2026
 (f)  Place of the transaction                                     Outside a trading venue

(d)

Aggregated information

-         Aggregated volume

-         Price

N/A

(e)

Date of the transaction

28 May 2026

(f)

Place of the transaction

Outside a trading venue

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBVLLLQELXBBE



            Copyright 2019 Regulatory News Service, all rights reserved